Nitec Pharma Raises Series B

Nitec Pharma AG, a Swiss drug company focused on the treatment of chronic inflammatory diseases, has raised approximately $26 million in Series B funding. NGN Capital led the deal, and was joined by return backers Atlas Venture and Global Life Science Ventures. www.nitecpharma.com